Table 1.
Clinical Characteristics of the Comparison Groups After Matching
| Characteristic | Daptomycin (n = 50) | Vancomycin (n = 100) | P Value |
|---|---|---|---|
| Variables used in the propensity score | |||
| Mean age, y | 58.34 | 61.64 | .27 |
| Male sex | 28 (56) | 62 (62) | .48 |
| Race | |||
| White | 36 (72) | 78 (78) | .42 |
| Black | 8 (16) | 10 (10) | .29 |
| Asian | 4 (8) | 10 (10) | .69 |
| Hispanic | 2 (4) | 2 (2) | .47 |
| Mean APACHE II score | 13.22 | 13.98 | .55 |
| Mean Charlson comorbidity index | 5.76 | 6.13 | .48 |
| Vancomycin MIC ≥2 mg/L (by broth microdilution) | 10 (20) | 22 (22) | .78 |
| Functional status | |||
| Independent | 17 (34) | 30 (30) | .62 |
| Partly dependent | 20 (40) | 40 (40) | 1 |
| Fully dependent | 13 (26) | 30 (30) | .61 |
| Total days of positive blood cultures prior to switch | 5 (±5.23) | 3.68 (±4.95) | .14 |
| Variables collected via chart review after matching | |||
| Liver disease (Child-Pugh B or greater) | 10 (20) | 20 (20) | 1 |
| Diabetes (type 1 or type 2) | 23 (46) | 36 (36) | .24 |
| Congestive heart failure (any stage) | 16 (32) | 25 (25) | .37 |
| Coronary artery disease | 16 (32) | 25 (39) | .4 |
| Solid malignancy | 2 (4) | 13 (13) | .083 |
| Hematologic malignancy | 2 (4) | 15 (15) | .045 |
| Chornic obstructive pulmonary disease | 8 (16) | 17 (17) | .88 |
| Prior surgery within 30 d | 1 (2) | 21 (21) | .002 |
| History of stroke | 6 (12) | 9 (9) | .56 |
| Endocarditis | 13 (26) | 11 (11) | .018 |
| Risk level of source | |||
| Low | 13 (26) | 6 (6) | <.001 |
| Intermediate | 17 (34) | 72 (72) | <.001 |
| High | 20 (40) | 22 (22) | .021 |
| Immunosuppression | 10 (20) | 20 (20) | 1 |
| HIV infection | 3 (6) | 3 (3) | .38 |
| Hemodialysis | 11 (22) | 19 (19) | .67 |
| Prior history of MRSA infection (not bloodstream) | 26 (52) | 42 (42) | .25 |
| Average GFR | 53.8 (±37.4) | 60.5 (±44.6) | .31 |
| GFR <50 mL/min/1.73 m2 | 27 (58) | 51 (51) | .42 |
| Creatinine clearance <30 mL/min | 12 (24) | 25 (25) | .99 |
| Outcomes | |||
| Failure composite outcome | 17 (34) | 51 (51) | .048 |
| In-hospital mortality | 8 (16) | 35 (35) | .015 |
| Persistent bacteremia | 7 (14) | 21 (21) | .3 |
| Recurrence | 6 (12) | 5 (5) | .12 |
Data are presented as No. (%) unless otherwise specified. The upper variables represent those baseline variables available and used in the construction of the propensity score acquired after an initial brief records review. The lower variables were collected after matching via additional records review. For the variable of “total days of positive blood cultures prior to a switch,” the total days of positive blood cultures was used for those patients in the vancomycin group.
Abbreviations: GFR, glomerular filtration rate; HIV, human immunodeficiency virus; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus.